PA8774101A1 - Compuesto de pirmidina - Google Patents

Compuesto de pirmidina

Info

Publication number
PA8774101A1
PA8774101A1 PA20088774101A PA8774101A PA8774101A1 PA 8774101 A1 PA8774101 A1 PA 8774101A1 PA 20088774101 A PA20088774101 A PA 20088774101A PA 8774101 A PA8774101 A PA 8774101A PA 8774101 A1 PA8774101 A1 PA 8774101A1
Authority
PA
Panama
Prior art keywords
compound
pirmidine
disorders
allergic
copd
Prior art date
Application number
PA20088774101A
Other languages
English (en)
Inventor
Pedgrift Brian
C Aldous Suzanne
W Fennie Michael
Z Jiang John
John Stanly
Mu Lan
R Pribish James
Rauckman Barbara
S Sabol Jeffrey
T Stoklosa Grzegorz
Thrurairatnam Sukanthini
L Vandeusen Christopher
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8774101A1 publication Critical patent/PA8774101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN COMPUESTO DE FORMULA (1): EN LA QUE R¹, R², R³, R4 Y L¹ SON COMO SE HAN DEFINIDO EN ESTE DOCUMENTO, A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO, Y AL USO DEL COMPUESTO PARA TRATAR TRASTORNOS ALERGICOS Y/O INFLAMATORIOS, PARTICULARMENTE TRASTORNOS TALES COMO RINITIS ALERGICA, ASMA Y/O ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA (COPD).
PA20088774101A 2007-03-30 2008-03-28 Compuesto de pirmidina PA8774101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90917107P 2007-03-30 2007-03-30

Publications (1)

Publication Number Publication Date
PA8774101A1 true PA8774101A1 (es) 2008-11-19

Family

ID=39494539

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088774101A PA8774101A1 (es) 2007-03-30 2008-03-28 Compuesto de pirmidina

Country Status (25)

Country Link
US (1) US8258130B2 (es)
EP (1) EP2142516B1 (es)
JP (1) JP5427769B2 (es)
KR (1) KR20090125852A (es)
CN (1) CN101646656B (es)
AR (1) AR065874A1 (es)
AU (1) AU2008232771B2 (es)
BR (1) BRPI0809974A2 (es)
CA (1) CA2682629C (es)
CL (1) CL2008000911A1 (es)
DK (1) DK2142516T3 (es)
ES (1) ES2400622T3 (es)
IL (1) IL200898A (es)
MA (1) MA31326B1 (es)
MX (1) MX2009009443A (es)
MY (1) MY154895A (es)
NZ (1) NZ579892A (es)
PA (1) PA8774101A1 (es)
PE (1) PE20090552A1 (es)
PT (1) PT2142516E (es)
RU (1) RU2464262C2 (es)
SG (1) SG179437A1 (es)
TW (1) TWI430994B (es)
WO (1) WO2008121670A1 (es)
ZA (1) ZA200906082B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2142516T3 (da) 2007-03-30 2013-04-15 Sanofi Sa Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer
WO2009029632A1 (en) * 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
NO2300013T3 (es) 2008-05-21 2018-02-03
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
CA2744563A1 (en) * 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
EP2266562A1 (en) * 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP2486024B1 (en) 2009-10-08 2015-04-22 Sanofi Phenyloxadiazole derivatives as pgds inhibitors
AT509045B1 (de) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
EP2576536B1 (en) 2010-06-01 2016-09-14 The University of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
BR112014012868B1 (pt) 2011-11-29 2019-12-17 Syngenta Participations Ag derivados de triazinona inseticidas, composição pesticida que os compreende, método para combater e controlar pragas e insetos da ordem hemiptera e material de propagação de plantas
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
RU2674028C2 (ru) * 2013-08-14 2018-12-04 Калвиста Фармасьютикалз Лимитед Ингибиторы ферментов
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
EP3165093A1 (en) 2015-11-05 2017-05-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
RU2018126105A (ru) 2015-12-17 2020-01-17 Астекс Терапьютикс Лимитед Хинолин-3-карбоксамиды в качестве ингибиторов h-pgds
IL293304A (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazole as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
UY37764A (es) 2017-06-13 2019-01-02 Glaxosmithkline Ip Dev Ltd Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
HRP20220367T1 (hr) 2017-11-29 2022-05-27 Kalvista Pharmaceuticals Limited Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
US20210139507A1 (en) 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds
JP2022506850A (ja) 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CA3183214A1 (en) 2020-06-19 2021-12-23 Motoaki Baba Condensed ring compounds that inhibit h-pgds
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
WO2023113023A1 (ja) * 2021-12-17 2023-06-22 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害するアザインドール誘導体
CN116514769B (zh) * 2022-01-21 2024-02-27 中国药科大学 4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143173A (ja) * 1984-08-06 1986-03-01 Mitsui Petrochem Ind Ltd 新規ピリミジン誘導体およびその製法
JPS61140568A (ja) * 1984-12-14 1986-06-27 Mitsui Petrochem Ind Ltd キナゾリン誘導体及びそれを有効成分とする血圧降下剤
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
RU2343148C2 (ru) * 2002-02-01 2009-01-10 Райджел Фармасьютикалз, Инк Соединения 2,4-пиримидиндиаминов и их применение
KR20050035885A (ko) 2002-08-16 2005-04-19 아벤티스 파마슈티칼스 인크. 마이크로솜성 프로스타글란딘 ｅ 신타제 또는 조혈성 프로스타글란딘 ｄ 신타제의 활성을 감소시키는 능력에 대해 화합물 또는 제제를 검정하는 방법
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
JP2007051121A (ja) * 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
BRPI0718874A2 (pt) * 2006-12-22 2015-06-23 Novartis Ag Compostos orgânicos
DK2142516T3 (da) 2007-03-30 2013-04-15 Sanofi Sa Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer
BRPI0809498A2 (pt) * 2007-04-02 2014-09-23 Inst Oneworld Health Compostos inibidores de cftr e seus usos

Also Published As

Publication number Publication date
BRPI0809974A2 (pt) 2014-10-07
JP5427769B2 (ja) 2014-02-26
AU2008232771A1 (en) 2008-10-09
AU2008232771B2 (en) 2012-12-20
AR065874A1 (es) 2009-07-08
IL200898A (en) 2013-12-31
PE20090552A1 (es) 2009-06-01
US8258130B2 (en) 2012-09-04
TWI430994B (zh) 2014-03-21
KR20090125852A (ko) 2009-12-07
ZA200906082B (en) 2010-06-30
CA2682629A1 (en) 2008-10-09
JP2010523494A (ja) 2010-07-15
CN101646656B (zh) 2013-08-14
DK2142516T3 (da) 2013-04-15
US20100048568A1 (en) 2010-02-25
RU2009140149A (ru) 2011-05-10
IL200898A0 (en) 2010-05-17
CA2682629C (en) 2013-03-19
PT2142516E (pt) 2013-03-07
ES2400622T3 (es) 2013-04-11
RU2464262C2 (ru) 2012-10-20
CL2008000911A1 (es) 2008-10-03
SG179437A1 (en) 2012-04-27
MX2009009443A (es) 2009-09-14
WO2008121670A1 (en) 2008-10-09
MY154895A (en) 2015-08-14
NZ579892A (en) 2012-03-30
EP2142516A1 (en) 2010-01-13
MA31326B1 (fr) 2010-04-01
TW200906802A (en) 2009-02-16
CN101646656A (zh) 2010-02-10
EP2142516B1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
PA8774101A1 (es) Compuesto de pirmidina
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
GT200900289A (es) Compuestos organicos.-
CL2019001334A1 (es) Pirrolopirimidinas como potenciadores de cftr.
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
UY31686A1 (es) Nueva dosificacion y formulacion
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
UY31687A1 (es) Nueva dosificacion y formulacion
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
CL2014000122A1 (es) Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.
CL2011002463A1 (es) Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica.
HN2011000874A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
CL2007003755A1 (es) Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
ECSP14013282A (es) 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureas como inhibidores de proteínas cinasas activadas por mitógeno p38
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
CL2008003494A1 (es) Compuestos derivados de 4-(2-amino-1-hidroxietil)fenol; composicion farmaceutica; combinacion; y uso de los compuestos como agonistas del receptor adrenergico beta2 para el tratamiento de una enfermedad pulmonar, asma, enfermedad pulmonar obstructiva cronica, glaucoma, trastornos neurologicos, trastornos cardiacos, inflamacion.
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
CL2007002791A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri
CL2007002159A1 (es) Uso de compuestos derivados de quinuclidina para tratar enfermedades tales como asma, enfermedad obstructiva cronica, bronquitis cronica, tos y enfisema; compuestos derivados de quinuclidina; composicion farmaceutica que comprende a dichos compuestos.
UY32938A (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
CR9191A (es) 4-feniltetrahidroisoquinolinas sustituidas, metodos para producirlas, su uso como farmaco y farmaco que las contiene
CL2011002461A1 (es) Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica.